TY - JOUR
TI - Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer
AU - Givalos, N.
AU - Gakiopoulou, H.
AU - Skliri, M.
AU - Bousboukea, K.
AU - Konstantinidou, A.E.
AU - Korkolopoulou, P.
AU - Lelouda, M.
AU - Kouraklis, G.
AU - Patsouris, E.
AU - Karatzas, G.
JO - Modern Pathology
PY - 2007
VL - 20
TODO - 2
SP - 159-166
PB - 
SN - 0893-3952, 1530-0285
TODO - 10.1038/modpathol.3800719
TODO - replication protein A;  replication protein A1;  replication protein A2;  unclassified drug, adult;  aged;  article;  cancer growth;  cancer patient;  cancer survival;  cancer therapy;  cancer tissue;  cell infiltration;  cell proliferation;  chemical labeling;  colon cancer;  controlled study;  female;  human;  human tissue;  immunohistochemistry;  lymph node metastasis;  male;  priority journal;  prognosis;  proportional hazards model;  protein expression;  statistical significance;  univariate analysis, Adenocarcinoma;  Adult;  Aged;  Aged, 80 and over;  Colon;  Colonic Neoplasms;  Female;  Humans;  Immunoenzyme Techniques;  Male;  Middle Aged;  Neoplasm Staging;  Prognosis;  Replication Protein A;  Retrospective Studies;  Survival Rate;  Tumor Markers, Biological
TODO - Replication protein A (RPA), a component of the origin recognition complex, is required for stabilization of single-stranded DNA at early and later stages of DNA replication being thus critical for eukaryotic DNA replication. Experimental studies in colon cancer cell lines have shown that RPA protein may be the target of cytotoxins designed to inhibit cellular proliferation. This is the first study to investigate the expression of RPA1 and RPA2 subunits of RPA protein and assess their prognostic value in colon cancer patients. We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in a series of 130 colon cancer resection specimens in relation to conventional clinicopathological parameters and patients' survival. Statistical significant positive associations emerged between: (a) RPA1 and RPA2 protein expressions (P=0.0001), (b) RPA1 and RPA2 labelling indices (LIs) and advanced stage of the disease (P=0.001 and 0.003, respectively), (c) RPA1 and RPA2 LIs and the presence of lymph node metastasis (P=0.002 and 0.004, respectively), (d) RPA1 LI and the number of infiltrated lymph nodes (P=0.021), (e) RPA2 LI and histological grade of carcinomas (P=0.05). Moreover, a statistical significant higher RPA1 LI was observed in the metastatic sites compared to the original ones (P=0.012). RPA1 and RPA2 protein expression associated with adverse patients' outcome in both univariate (log rank test: P<0.00001 and 0.00001, respectively) and multivariate (Cox model: P=0.092 and 0.0001, respectively) statistical analysis. Statistical significant differences according to the expression of RPA1 and RPA2 proteins were also noticed in the survival of stage II (P<0.00001 and 0.0016, respectively) and stage III (P=0.0029 and 0.0079, respectively) patients. In conclusion, RPA1 and RPA2 proteins appear to be useful prognostic indicators in colon cancer patients and attractive therapeutic targets for regulation by tumor suppressors or other proteins involved in the control of cell proliferation. © 2007 USCAP, Inc All rights reserved.
ER -